Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | F3 | P13726 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642818 | 0.84 | AHR (0.52) | AHRCYP2A6GPR84TRPA1CA1 | |
| SCHEMBL5134026 | 0.80 | AHR (0.52) | AHRNR4A2CYP2A6GAAF7 | |
| SCHEMBL27255151 | 0.79 | AHR (0.47) | AHRNR4A2CYP2A6GAAF7 | |
| SCHEMBL13230543 | 0.79 | AHR (0.47) | AHRNR4A2CYP2A6GAAF7 | |
| SCHEMBL31543700 | 0.79 | AHR (0.52) | AHRNR4A2CYP2A6GAAF7 | |
| SCHEMBL31543727 | 0.77 | AHR (0.44) | AHRNR4A2CYP2A6GAAF7 | |
| SCHEMBL2889663 | 0.75 | NPC1 (0.56) | AHRNR4A2CYP2A6GAAF7 | |
| SCHEMBL31543723 | 0.75 | AHR (0.43) | AHRNR4A2CYP2A6GAAF7 | |
| SCHEMBL30138435 | 0.74 | AHR (0.56) | AHRNR4A2CYP2A6GAAF7 | |
| SCHEMBL30882 | 0.74 | AHR (0.56) | AHRNR4A2CYP2A6GAAF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12606543-B2 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | MINDSET PHARMA INC. (CA) | 2026-04-21 | — | — | US | disclosed |
| US-20260092035-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC (CA) | 2026-04-02 | — | — | US | disclosed |
| US-20260078090-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC. | 2026-03-19 | — | — | US | disclosed |
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250263760-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250257034-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC (CA) | 2025-08-14 | — | — | US | disclosed |
| US-20250250256-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2025-08-07 | — | — | US | disclosed |
| US-12319946-B2 | Methods for producing modified bacteria for production of nitroaromatics | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-06-03 | — | — | US | disclosed |
| WO-2025104490-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2025-05-22 | — | — | WO | disclosed |
| US-20050101623-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005009370-A2 | BETA-CARBOLINE COMPOUNDS AND ANALOGUES THEREOF AND THEIR USE AS MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
| EP-1109813-B1 | PYRROLOINDOLES, PYRIDOINDOLES AND AZEPINOINDOLES AS 5-HT2C AGONISTS | VERNALIS RES LTD (GB) | 2004-08-11 | — | — | EP | disclosed |
| US-6433175-B1 | ANTISEROTONINE AGENTS | VERNALIS RESEARCH LIMITED (GB) | 2002-08-13 | — | — | US | disclosed |
| WO-1992007829-A1 | INDOLE-3-METHANAMINES USEFUL AS ANTI-DIABETIC, ANTI-OBESITY AND ANTI-ATHEROSCLEROTIC AGENTS | THE UPJOHN COMPANY (US) | 1992-05-14 | — | — | WO | disclosed |
| EP-0022705-B1 | DERIVATIVES OF TETRAHYDROPYRIDINYL-INDOL AND THEIR SALTS, THEIR PREPARATION, THEIR APPLICATION AS MEDICINES, AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1983-04-06 | — | — | EP | disclosed |
| US-4333939-A | ANTIDEPRESSANTS, ANTIPARKINSON, ANTIEMETICS | ROUSSEL UCLAF (FR) | 1982-06-08 | — | — | US | disclosed |
| US-4324790-A | NEUROLEPTIC, ANTIEMETIC | ROUSSEL UCLAF (FR) | 1982-04-13 | — | — | US | disclosed |
| EP-0022705-A1 | Derivatives of tetrahydropyridinyl-indol and their salts, their preparation, their application as medicines, and compositions containing them | ROUSSEL-UCLAF (FR) | 1981-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078090-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, TPH1, HTR3D | AHR 501/4885NR4A2 881/4885CYP2A6 982/4885 |
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | HTR4, OPRM1, HTR7 | AHR 310/4885NR4A2 146/4885CYP2A6 548/4885 |
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, HTR2C, TPH1 | AHR 501/4885NR4A2 1825/4885CYP2A6 718/4885 |
| US-20250250256-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, TPH2, HTR5A | AHR 255/4885NR4A2 3438/4885CYP2A6 728/4885 |
| US-20250257034-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, TPH2, HTR5A | AHR 198/4885NR4A2 3199/4885CYP2A6 559/4885 |
| US-20050101623-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAP4K2, MAPKAPK2, MAP3K2 | AHR 2713/4885NR4A2 1834/4885CYP2A6 4676/4885 |
| US-20260092035-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR6, HTR3C, CNR1 | AHR 102/4885NR4A2 1865/4885CYP2A6 93/4885 |
| US-12606543-B2 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | HTR6, CNR1, HTR3C | AHR 165/4885NR4A2 2074/4885CYP2A6 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.